Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of Hepatitis C (HCV) patients. The key driver of the Chinese…
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…
What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…